Abstract :
COVID-19 virus outbreak was first found in Wuhan China. The current COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-CoV-2). The interaction of the virus with the immune system causes the immunity of people affected by the outbreak to decrease. The combination of nanogold and nanosilver, that is an antimicrobial and antiviral agent, can inhibit the replication of the COVID-19 virus an d act as drug delivery. This research aims to determine the effect of nanogold-nanosilver that can increase immunity in people who are positively affected by the COVID-19 virus. The method used in this research was quantitative descriptive by describing the effect of the nanogold-nanosilver health drink given to increasing human immunity exposed to the COVID-19 virus seen from the number of respondent cures. The respondents consumed 500 mL of health drinks containing nanogold and nanosilver compounds with a concentration of 2 ppm per day. Based on the data obtained, the combination of nanogold and nanosilver could increase the immunity of people affected by COVID-19, marked by physical changes that became healthier, fitter and negative swab test results and accelerate the healing of COVID-19 patients.
Keywords :
COVID-19, drug delivery, Immunity, nanogold, nanosilverReferences :
1. Z. Wu and J. M. McGoogan, “Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention,” JAMA – J. Am. Med. Assoc., vol. 323, no. 13, pp. 1239–1242, 2020, doi: 10.1001/jama.2020.2648.
2. World Health Organization (WHO), “Coronavirus disease 2019 (2019-nCOV) Situation Report – 11,” 2020.
3. https://nasional.okezone.com/, “Update Corona di Indonesia Desember 2020,” 2020.
4. A. G. F. Brooks, K. C. Carroll, J. S. Butel, and S. A. Morse, Medical Microbiology 24 th Edition, vol. 7, no. 3. 2007.
5. A. E. Gorbalenya et al., “The species and its viruses – a statement of the Coronavirus Study Group,” Biorxiv (Cold Spring Harb. Lab., pp. 1–15, 2020, [Online]. Available: https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1.full.
6. Y. Han, “The transmission and diagnosis of 2019 novel coronavirus infection disease ( COVID ‐ 19 ): A Chinese perspective,” no. March, pp. 639–644, 2020, doi: 10.1002/jmv.25749.
7. S. W. X. Ong et al., “Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) from a Symptomatic Patient,” JAMA – J. Am. Med. Assoc., vol. 323, no. 16, pp. 1610–1612, 2020, doi: 10.1001/jama.2020.3227.
8. H. Zhang, J. M. Penninger, Y. Li, N. Zhong, and A. S. Slutsky, “Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target,” Intensive Care Med., vol. 46, no. 4, pp. 586–590, 2020, doi: 10.1007/s00134-020-05985-9.
9. B. Aylward and W. Liang, “Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19),” 2020. [Online]. Available: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.
10. L. Dong, S. Hu, and J. Gao, “Discovering drugs to treat coronavirus disease 2019 (COVID-19),” Drug Discov. Ther., vol. 14, no. 1, pp. 58–60, 2020, doi: 10.5582/ddt.2020.01012.
11. A. H. Mansourabadi, M. Sadeghalvad, H. R. Mohammadi-Motlagh, and N. Rezaei, “The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19,” Life Sci., vol. 258, no. August, p. 118185, 2020, doi: 10.1016/j.lfs.2020.118185.
12. T. Taufikurohmah, G. M. Sanjaya, A. Baktir, and A. Syahrani, “Activity Test of Nanogold for Reduction of Free Radicals, a Pre-Assessment Utilization Nanogold in Pharmaceutical as Medicines and Cosmetics,” J. Mater. Sci. Eng. B, vol. 2, no. 12, pp. 611–617, 2012.
13. T. Taufikurohmah, D. Winarni, A. Baktir, I. G. M. Sanjaya, and A. Syahrani, “Histology Study : Pre-Clinic Test of Nanogold in Mus Musculus Skin , at Fibroblast Proliferation and Collagen Biosynthesis,” vol. 3, no. 5, pp. 55–60, 2013.
14. D. Baram-Pinto, S. Shukla, A. Gedanken, and R. Sarid, “Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles,” Small, vol. 6, no. 9, pp. 1044–1050, 2010, doi: 10.1002/smll.200902384.
15. T. Taufikurohmah and D. Soepardjo, “Herpes Disease : Case Study Of Herpes Transmission In Islamic Cottage Schools,” vol. 1, pp. 88–94, 2019.
16. J. H. Johnston and T. Nilsson, “Nanogold and nanosilver composites with lignin-containing cellulose fibres,” J. Mater. Sci., vol. 47, no. 3, pp. 1103–1112, 2012, doi: 10.1007/s10853-011-5882-0.
17. T. Taufikurohmah, A. P. Wardana, S. Tjahjani, I. G. M. Sanjaya, A. Baktir, and A. Syahrani, “The Clinical Test of Nano gold Cosmetic for Recovering Skin Damage Due to Chemicals: Special Case,” J. Phys. Conf. Ser., vol. 947, no. 1, pp. 0–5, 2018, doi: 10.1088/1742-6596/947/1/012056.
18. S. Vikas, K. S. Krishan, and K. S. Manjit, “Nanosilver: Potent antimicrobial agent and its biosynthesis,” African J. Biotechnol., vol. 13, no. 4, pp. 546–554, 2014, doi: 10.5897/ajb2013.13147.
19. H. H. Lara, N. V. Ayala-Nuñez, L. Ixtepan-Turrent, and C. Rodriguez-Padilla, “Mode of antiviral action of silver nanoparticles against HIV-1,” J. Nanobiotechnology, vol. 8, pp. 1–10, 2010, doi: 10.1186/1477-3155-8-1.
20. R. M. Rosa, J. C. Silva, I. S. Sanches, and C. Henriques, “Simultaneous photo-induced cross-linking and silver nanoparticle formation in a PVP electrospun wound dressing,” Mater. Lett., vol. 207, pp. 145–148, 2017, doi: 10.1016/j.matlet.2017.07.046.
21. I. V. Kiseleva et al., “Anti-influenza effect of nanosilver in a mouse model,” Vaccines, vol. 8, no. 4, pp. 1–17, 2020, doi: 10.3390/vaccines8040679.
22. X. Lv et al., “Biomaterials Inhibitory effect of silver nanomaterials on transmissible virus-induced host cell infections,” Biomaterials, vol. 35, no. 13, pp. 4195–4203, 2014, doi: 10.1016/j.biomaterials.2014.01.054.
23. P. Mishra, M, Chauhan, “Nanosilver and its Medical Implications,” vol. 2, no. 5, pp. 1–10, 2015, doi: 10.15406/jnmr.2015.02.00039.
24. Z. Xiang et al., “Gold Nanoparticles Inducing Osteogenic Differentiation of Stem Cells: A Review,” J. Clust. Sci., vol. 29, no. 1, 2018, doi: 10.1007/s10876-017-1311-0.
25. A. S. Levina, M. N. Repkova, N. A. Mazurkova, and V. F. Zarytova, “Nanoparticle-Mediated Nonviral DNA Delivery for Effective Inhibition of Influenza a Viruses in Cells,” IEEE Trans. Nanotechnol., vol. 15, no. 2, pp. 248–254, 2016, doi: 10.1109/TNANO.2016.2516561.
26. Y. Li et al., “Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways,” ACS Appl. Mater. Interfaces, vol. 8, no. 37, pp. 24385–24393, 2016, doi: 10.1021/acsami.6b06613.
27. M. A. Elkodous, “Engineered nanomaterials as fighters against SARS-CoV-2 : The way to control and treat pandemics,” Environ. Sci. Pollut. Res., 2020, doi: 10.1007/s11356-020-11032-3.
28. E. Boisselier and D. Astruc, “Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity,” Chem. Soc. Rev., vol. 38, no. 6, pp. 1759–1782, 2009, doi: 10.1039/b806051g.
29. C. A. Dos Santos et al., “Silver nanoparticles: Therapeutical uses, toxicity, and safety issues,” J. Pharm. Sci., vol. 103, no. 7, pp. 1931–1944, 2014, doi: 10.1002/jps.24001.
30. N. Fadhilah and S. Megantara, “Penggunaan Nanopartikel Emas Dalam Teknologi Untuk Diagnosis Kanker,” Farmaka, vol. 16, no. 2, pp. 254–263, 2018.
31. L. A. Dykman and N. G. Khlebtsov, “Gold Nanoparticles in Biology and Medicine : Recent Advances and Prospects,” vol. 3, no. 9, pp. 34–55, 2011.
32. A. Zuber et al., “Detection of gold nanoparticles with different sizes using absorption and fluorescence based method,” Sensors Actuators, B Chem., vol. 227, pp. 117–127, 2016, doi: 10.1016/j.snb.2015.12.044.
33. A. Timoszyk, “A review of the biological synthesis of gold nanoparticles using fruit extracts: Scientific potential and application,” Bull. Mater. Sci., vol. 41, no. 6, pp. 1–11, 2018, doi: 10.1007/s12034-018-1673-4.
34. A. Salleh et al., “The potential of silver nanoparticles for antiviral and antibacterial applications: A mechanism of action,” Nanomaterials, vol. 10, no. 8, pp. 1–20, 2020, doi: 10.3390/nano10081566.
35. S. Gurunathan et al., “Antiviral potential of nanoparticles—can nanoparticles fight against coronaviruses?,” Nanomaterials, vol. 10, no. 9, pp. 1–29, 2020, doi: 10.3390/nano10091645.